Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.

J Oncol Pharm Pract · 2019 · PMC6643159 · PMID 30924737

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

However, the difference in mean time for administering each drug failed to reach statistical significance ( Table 3 ).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.